- Zacks Small Cap Research•2 days ago
CytoSorbents (CTSO) has had a busy last couple of months leading up to the annual JP Morgan, Biotech Showcase and Medtech Showcase conferences which were held earlier this week in San Francisco and where management took some time to talk to us. Just prior to the company’s presentation at the Biotech Showcase they announced an expanded agreement with Fresenius and preannounced expected Q4 and FY2016 product sales. Per the January 10th preannouncement, CTSO expects Q4 product sales of ~$2.6M, implying sequential and yoy growth of approximately 21% and 74%, respectively, and marking the sixth straight quarter of record product sales. Product sales of $2.6M is also almost 16% higher than what we had forecast ($2.2M).
- Business Wire•5 days agoStatement of Fresenius Medical Care North America Regarding U.S. Court Ruling Granting Temporary Restraining Order
In response to the U.S. District Court’s ruling today granting a temporary restraining order regarding charitable contributions for premium assistance, Fresenius Medical Care North
- Business Wire•9 days agoIMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Fresenius Medical Care AG & Co. KGAA and Advises Investors with Losses to Contact the Firm
Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Fresenius Medical Care AG & Co. KGAA concerning possible violations of federal securities laws.
FMS : Summary for Fresenius Medical Care AG Commo - Yahoo Finance
Fresenius Medical Care AG & Co. KGAA (FMS)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.00 - 0.00|
|52 Week Range|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||21.38|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|